All articles tagged with #biopharmaceuticals
Pfizer raised its 2025 profit outlook despite a 6% decline in quarterly sales and an 18% drop in earnings, leading to a slight dip in stock price, as the company reported better-than-expected earnings per share but maintained conservative full-year sales guidance amid mixed division performances.
AstraZeneca plans to invest $50 billion in the US by 2030 to expand manufacturing and research, including a major new facility in Virginia, as part of its response to US trade tariffs and to bolster its US market presence, aiming for $80 billion in annual revenue by 2030.
Poseida Therapeutics, a clinical-stage biopharmaceutical company, has agreed to be acquired by Roche Holdings for up to $1.5 billion. Poseida stockholders will receive $9.00 per share in cash at closing, plus a contingent value right for up to an additional $4.00 per share. The acquisition will enhance Roche's capabilities in allogeneic cell therapy, particularly in CAR-T programs for cancer and autoimmune diseases. The transaction is expected to close in the first quarter of 2025, pending regulatory approvals and other conditions.
4D Molecular Therapeutics has acquired the rights to the short-form human complement factor H (sCFH) asset from Aevitas Therapeutics, a subsidiary of Fortress Biotech. Meanwhile, Boehringer Ingelheim has inaugurated a new Germany-based research center, into which the company invested €350 million, to strengthen its biopharmaceuticals development. Additionally, Eli Lilly is planning to start testing its weight loss treatment candidate in a head-to-head clinical trial against Novo Nordisk’s Wegovy this month.
Harvard geneticists have developed a bacteria, E. coli, that is immune to all viruses by altering its genetic code using a special type of RNA called transfer RNA (tRNA). The team added "trickster" tRNAs that install a different amino acid, creating non-functional virus proteins and blocking replication. The bacteria's modified genes cannot escape into the wild due to two safety mechanisms. The research could have implications for bacteria-based production, including the production of biopharmaceuticals, and may provide a general strategy to make any organism safely resistant to all natural viruses.